Subject: Clinics for the Future. Barrons article on DNAP !!
From: None <Listmember3@aba.com>
Date: 09/24/2000 00:43:17
Dnaprint Genomics (DNAP) is in this weeks issue of Barrons page 52.
Clinics of the future will read genetic data from patients saliva or blood and screen this "read" against "solutions" generated genomics companies.
Dnaprint Genomics (DNAP) intends to be the first to establish tools for these diagnostic solutions.
DNAP is trading at 23.5 CENTS at Friday's (9/22/00) close. We feel this is an excellent opportunity to profit from the ground floor on an emerging biotech company that started trading recently by an effective reverse merger with a company that was on the pink sheets.
The CEO Tony Frudakis was a lead scientist for Corixa. Corixa's stock has gone from 14 cents to 49 dollars (Fridays close) within a few years, partly due to Dr. Frudakis's patent developement. Dr. Frudakis decided to start his own company.
Frudakis, 33, said he expects DNAprint to become a Fortune 500 company within 10 years.
For the article on DNAP see this week's Barrons (Sept 25,2000 issue) page 52. It's against copyright laws to post the article without permission.
This is not from a registered financial advisory, please consult with a registered investment advisor before making an investment decision. This communication (print or electronic) reflects our opinions and does not necessarily reflect those of anyone else related to the firm and may be in conflict with the views or official views of the companies mentioned. Readers are advised that this publication (print or electronic) is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This communication is based on information available to the public.
We are NOT a professional advisory service, broker, investment firm or agency.
We are NOT a stock picking service. The securities profiled here are solely of our own opinion and it is not recommended that you buy, sell, or hold based on what you find here. Please continue to perform your own Due Diligence. Any investment decisions you make should be your own predicated upon your own findings and judgments born from your own research. All images and logo's used to represent DNAPrint are registered trademarks of DNAPrint. Barrons is a registered trademark of Dow Jones & Co., Inc..